Topiramate (Qudexy XR) vs Topiramate (Trokendi XR)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Epilepsy
Shared mechanism: Voltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydrase · full Epilepsy pipeline
Topiramate (Qudexy XR)
Marketed by Upsher-Smith Laboratories, LLC
NCT01142193 · Phase 3 · completed
This was a randomized, double-blind, placebo-controlled trial of 249 participants. The primary clinical endpoint—percent reduction in weekly partial-onset seizure frequency over 11 weeks—was met, with a statistically significant advantage for USL255 over placebo (p<0.001).
Reported efficacy
Percent Reduction From Baseline in Weekly (7 Day) Partial-onset Seizure Frequency During the Titration Plus Maintenance Phase Compared to Baseline. (11 weeks): Percent Reduction From Baseline in Weekly (7 Day) Partial-onset Seizure Frequency During the Titration Plus Maintenance Phase Compared to Baseline. (11 weeks): USL255 39.5 Percent Reduction (range -227.3 to 100) | Placebo 21.65 Percent Reduction (range -531.2 to 100) (met)
Result source: NCT01142193
Topiramate (Trokendi XR)
Marketed by Supernus Pharmaceuticals
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Results for Epilepsy
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Topiramate (Qudexy XR) | Topiramate (Trokendi XR) |
|---|---|---|
| Seizure frequency, % change | —Not posted · NCT00236717 | —Not posted · NCT00236717 |
| 50% responder rate | 33.9% vs 17.6%+16.3 vs placeboNCT01142193 | —Not posted · NCT00236717 |
| Seizure freedom | —Not posted · NCT00236717 | —Not posted · NCT00236717 |
Seizure frequency, % change
- Topiramate (Qudexy XR)
- —Not posted · NCT00236717
- Topiramate (Trokendi XR)
- —Not posted · NCT00236717
50% responder rate
- Topiramate (Qudexy XR)
- 33.9% vs 17.6%+16.3 vs placeboNCT01142193
- Topiramate (Trokendi XR)
- —Not posted · NCT00236717
Seizure freedom
- Topiramate (Qudexy XR)
- —Not posted · NCT00236717
- Topiramate (Trokendi XR)
- —Not posted · NCT00236717
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Topiramate (Qudexy XR): 4 of 4 rows · Topiramate (Trokendi XR): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Topiramate (Qudexy XR) | Topiramate (Trokendi XR) |
|---|---|---|
| Dropout rate | 16.9% NCT01142193 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3 | 29.5%a NCT01191086 · Phase 3 · registry result, not featured evidence |
| Discontinued due to AEs | 9.7% NCT01142193 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3 | 9.5%a NCT01191086 · Phase 3 · registry result, not featured evidence |
| Serious AEs | 1.6% NCT01142193 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3 | 6.7%a NCT01191086 · Phase 3 · registry result, not featured evidence |
| Most frequent reported AEs | somnolence 12.1% (placebo 2.4%) dizziness 7.3% (placebo 5.6%) paraesthesia 6.5% (placebo 2.4%) NCT01142193 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3 | a headache 7.6% weight decreased 7.6% somnolence 7.1% NCT01191086 · Phase 3 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Topiramate (Qudexy XR)
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Topiramate (Qudexy XR)'s landscape · Topiramate (Trokendi XR)'s landscape